Davis Robert M 4

What Happened
Robert M. Davis (Chairman, CEO & President, Director) reported two open-market sales on Feb 4, 2026, disposing of a total of 47,434 Merck (MRK) shares for aggregate proceeds of $5,599,327. The first block was 14,972 shares at a weighted avg price of $117.38 (proceeds $1,757,407); the second was 32,462 shares at a weighted avg price of $118.35 (proceeds $3,841,920). These were sales (not purchases), which are often routine liquidity or diversification actions rather than explicit signals about company prospects.

Key Details

• Transaction dates: February 4, 2026; Form 4 filed February 6, 2026 (filed within the usual two-business-day reporting window).
• Sales and prices:
  • 14,972 shares sold @ weighted avg $117.38 (range $116.96–$117.95) — $1,757,407 proceeds. (Footnote F1)
  • 32,462 shares sold @ weighted avg $118.35 (range $118.00–$118.71) — $3,841,920 proceeds. (Footnote F2)
• Total: 47,434 shares sold for $5,599,327.
• Shares owned after transaction: not specified in the information provided in your prompt / not disclosed here.
• Notable footnotes: prices reported are weighted averages and represent multiple trades across the stated price ranges; the reporting person will provide a break-down of quantities at each price on request (per F1 and F2).
• Transaction code: S = Sale.

Context
Insider sales are common for personal liquidity, tax or portfolio-management reasons and do not by themselves prove a change in insider sentiment. For retail investors, purchases typically carry more informational weight than routine sales. No options exercise, grant, gift, or 10%‑owner transaction is indicated in this filing.